How much could $10,000 invested in CSL shares be worth next year?

Do analysts think it would be worth sinking money into this top stock?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're fortunate enough to have $10,000 sitting in your savings account and no immediate use for it, then it could be worth putting it to work in the share market.

After all, with a historic return in the region of 10%, that $10,000 could become $11,000 in 12 months if history were to repeat itself.

In addition, if you can find an ASX share with market-beating potential, then you could grow your wealth even more.

But which shares could do this? Could CSL Ltd (ASX: CSL) shares beat the market? Let's find out.

A man thinks very carefully about his money and investments.

Image source: Getty Images

$10,000 invested in CSL shares

At present, the CSL share price is trading at $289.24. This means that if you were to invest $10,000 (and a further $123.40), you would end up owning 35 units.

According to a recent note out of Morgans, its analysts see scope for the company's shares to rise from current levels. The broker said:

While shares have struggled of late, we continue to view CSL as a key portfolio holding and sector pick, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average.

Morgans has an add rating and $315.35 price target on CSL's shares. This implies potential upside of 9% and values those 35 units at $11,037.25.

Bigger returns

The good news is that even bigger returns could be on the cards according to analysts at Macquarie.

A recent note out of the investment bank reveals that its analysts have an outperform rating and $330.00 price target on the company's shares. This suggests that upside of 14.1% is possible over the next 12 months.

If this recommendation proves accurate, those 35 CSL shares would have a market value of $11,550. That's almost $1,500 greater than your original investment.

But it gets better. Macquarie is feeling very positive about the outlook of the CSL Behring business. This is particularly important given how it is far and away the biggest contributor to CSL's overall earnings.

As a result, the broker sees scope for CSL's shares to rise significantly over the next three years thanks to the strength of the CSL Behring business. So much so, it believes that a share price of $500 is possible by 2027.

If that happens, it would mean those 35 shares will be worth a sizeable $17,500. That's a very large increase on the original outlay of $10,123.40.

Here's hoping that Macquarie is on the money with its recommendation and valuation.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

ASX share investor sitting with a laptop on a desk, pondering something.
Share Fallers

CSL shares crash to a 9-year low. Is it time to sell off my shares?

What's next for the beaten-down ASX biotech stock?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

This ASX biotech hit a 90% success rate. Can it unlock commercial growth?

Orthocell is already seeing growing adoption, with more than 300 surgeons across over 220 hospitals in Australia using Remplir.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

This ASX biotech is pushing for a Nasdaq listing. Could it reignite investor interest?

The NASDAQ has a reputation for providing a platform for some of the world's most innovative companies.

Read more »

Smiling health care workers in a medical setting.
Healthcare Shares

3 ASX healthcare shares to buy amid sector rout: experts

Healthcare shares have tumbled 36% over the past year amid multiple headwinds for the sector.

Read more »

Person pressing the buy button on a smartphone.
Broker Notes

3 reasons to buy Pro Medicus shares today

A leading analyst believes Pro Medicus shares are now trading at a significant discount.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX biotech has just announced a major US deal

This company's heart disease technology is gaining traction.

Read more »

Devastated woman sits near smartphone on home kitchen floor troubled with loneliness.
Healthcare Shares

Which beaten down ASX healthcare stock is a better buy right now: Pro Medicus vs Cochlear shares

Which do experts prefer?

Read more »

Health professional working on his laptop.
Healthcare Shares

Already up 42% this year, Morgans says this ASX healthcare stock can continue to rocket

This broker sees big upside for this healthcare stock.

Read more »